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Tumor immunity represents a new avenue for cancer therapy. Immune checkpoint inhibitors have
successfully improved outcomes in several tumor types. In addition, currently, immune cell-based
therapy is also attracting significant attention. However, the clinical efficacy of these treatments re-
quires further improvement. The mechanisms through which cancer cells escape the immune response
must be identified and clarified. Cancer stem cells (CSCs) play a central role in multiple aspects of
malignant tumors. CSCs can initiate tumors in partially immunocompromised mice, whereas non-CSCs
fail to form tumors, suggesting that tumor initiation is a definitive function of CSCs. However, the fact
that non-CSCs also initiate tumors in more highly immunocompromised mice suggests that the im-
mune evasion property may be a more fundamental feature of CSCs rather than a tumor-initiating
property. In this review, we summarize studies that have elucidated how CSCs evade tumor immu-
nity and create an immunosuppressive milieu with a focus on CSC-specific characteristics and func-
tions. These profound mechanisms provide important clues for the development of novel tumor
immunotherapies.
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Tumor tissues consist of various types of noncancerous cells,
including vascular and immune cells. Drugs targeting the VEGF/
VEGFR signaling pathway, such as bevacizumab, ramucirumab,
aflibercept, and regorafenib, suppress the proliferation of endo-
thelial cells in tumor tissues, thereby inhibiting neovascularization
in the tumor microenvironment [1]. The infiltration of immune
cells, including CD4þ and CD8þ T cells, dendritic cells (DCs), and
natural killer (NK) cells, into tumors is associated with the prog-
nosis of patients with cancer. These immune cells are frequently
suppressed by immune checkpointmolecules, such as programmed
death receptor-1 (PD-1), its ligands (PD-L1/PD-L2), and cytotoxic T-
cell-associated antigen-4 (CTLA-4), which may be restored by
checkpoint inhibitors [2]. Within tumors, noncancerous cells with
tumor-specific functions, including cancer-associated fibroblasts
(CAFs) [3], tumor-associated macrophages (TAMs) [4], tissue-
associated neutrophils [5], myeloid-derived suppressor cells
(MDSCs) [6], and pericytes [7], also exist. These cells can promote
tumor growth, recurrence, and metastasis through direct and in-
direct interactions with cancer cells [8]. Recently, it has been
revealed that bacteria cells may reside within cancer and immune
cells. These intratumoral bacteria affect tumor malignancy and
response to immunotherapy [9]. Because of their important role in
tumor growth and progression, these noncancerous cells have
attracted significant interest as therapeutic targets for the devel-
opment of novel cancer medicines.
Besides noncancerous cells, cancer cells exhibit genetically and
nongenetically heterogeneous populations within tumor tissue.
The genetic heterogeneity of cancer cells may occur as a conse-
quence of genetic and chromosomal instabilities [10,11] and may
cause significant difficulties to the overall effectiveness of precision
medicine. In contrast, the nongenetic heterogeneous populations,
in particular, cancer stem cells (CSCs) and non-CSCs, were found in
tumor tissue. CSCs have distinct properties compared with non-
CSCs, including self-renewal, differentiation into non-CSCs, and
tumor initiation ability. Interestingly, non-CSCs can revert to CSCs
without alteration of genomic sequences [12,13], indicating that
their relation is, in part, different from that of normal stem/pro-
genitor cells compared with their descendant cells. Because of their
malignant characteristics, CSCs are also involved in recurrence,
metastasis, and resistance to chemotherapy and radiotherapy.
Therefore, CSCs are attracting attention as novel target for pre-
vention and treatment of cancer.
Immune cells actively survey and eliminate cells undergoing
malignant transformation. However, some of the transformed cells
can evade immune surveillance and eventually form tumor. This
suggests that immune evasion may also be a malignant feature of
CSCs. Interestingly, immunomodulating properties have also been
observed in normal stem cells [14]. Likewise, CSCs can create an
immunosuppressive milieu by cooperating with other21noncancerous cells in the tumor microenvironment. This function
is not only intrinsic to CSCs but also extrinsic from noncancerous
cells. Therefore, clarifying this mechanism and the immunological
features of CSCs will increase our understanding of tumor devel-
opment and recurrence and provide novel therapeutic targets for
cancer immunotherapy. In this review, we summarize the current
literature regarding the relation between CSCs and tumor immu-
nity, and the manner in which CSCs evade and protect tumors from
immune surveillance and destruction.
2. Tumorigenicity in immune-compromised/competent mice
CSCs were first identified from leukemia cells using severe
combined immunodeficient (SCID) mice [15], inwhich mature T and
B cells are depleted, but the innate immune cells, including NK cells
and macrophages, are retained. Thereafter, CSCs in solid tumors
were identified using nonobese diabetic (NOD)/SCID mice [16], in
which innate immunity activity is lower compared with SCID mice
but still present. These experiments using partially immunocom-
promised mice demonstrated that a small subset of cancer cells can
initiate tumor development. However, Quintana et al. [17] reported
that tumor-initiating cells in human melanoma were not a rare
population when transplanted into more highly immunocompro-
mised NOD/SCID IL-2 receptor gamma chain null (NSG) mice, in
which NK, T, and B cells are deficient. They showed that the fre-
quency of melanoma-initiating cells determined by NOD/SCID mice
was 1/106e1/105, whereas that of NSG mice was 1/9e1/4 [17].
Consistently, xenotransplantation of non-CSCs into NSG mice also
resulted in tumor formation (Fig. 1), and tumor initiation was not
associated with the expression of known melanoma CSC markers
(CD271 and ATP-binding cassette B5), which are established in-
dicators of tumor initiation in NOD/SCID mice [17,18]. However, in
tumor tissues developed from CD271-negative melanoma cells
transplanted into NSG mice, the expressions of melanoma markers,
such as melanocyte-inducing transcription factor (MITF) and SP100,
were no longer retained [19], suggesting the failure of self-renewal
(Fig. 1). Moreover, these CD271-negative cells also failed to passage
in NSG mice, whereas CD271-positive CSCs were successively
propagated (Fig. 1) [19]. A similar observation was reported for
CD133-positive and CD133-negative hepatocellular carcinoma cells
in a syngeneic transplantation model [20]. Interestingly, after
transplanting CD271-positive melanoma CSCs into NSG mice, the
tumor cells did not show a similar expression pattern of melanoma
markers compared with that in parental tumor tissues [19], sug-
gesting that immune selection may be required for the maintenance
of the self-renewal property (Fig. 1). The differences observed be-
tween NOD/SCID and NSG mice indicate that the tumor initiation
property is a more frequent and ubiquitous feature and that the
rarity of cancer cells exhibiting tumor-initiating properties may not
be so important for CSC definition. Rather, tumor immune evasion
may be a more important characteristic of CSCs [21,22]. Because
Fig. 1. Tumorigenicity in immune-compromised/competent mice. Details are discussed in the main text.
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represent a fundamental stemness property endowed on CSCs
[14,23,24].
As described above, immune selection, which is a phenomenon
that immune cells preferentially kill non-CSCs, and consequently
promote the propagation of CSCs, may play a role in CSC mainte-
nance and induction (Fig. 1). In other words, this phenomenon in-
dicates that CSCs have an immune evasion property, and are
capable to grow even under the surveillance of the immune system.
A human hepatoma cell line, HepG2 cells, exposed to mouse
macrophages or B cells exhibited increased CSC properties,
concomitant with the upregulation of CSC markers [25]. In mice,
cytotoxic CD8þ T lymphocytes (CTL) enriched CD24/low/CD44þ
breast CSCs by inducing the epithelialemesenchymal transition
(EMT) [26]. Trastuzumab, a specific antibody against HER2, kills
HER2-positive breast cancer cells by NK-cell-mediated antibody-
dependent cytotoxicity (ADCC). After ADCC, surviving breast cancer
cells formed spheroids exhibiting a CD44high/CD24low CSC-like
phenotype and lower HER2 expression compared with parental
cells [27]. The immune selection of malignant rhabdoid tumor cells
by passaging in immunocompetent mice enriched cells with
increased CSC properties and decreased expression of major his-
tocompatibility complex (MHC) molecules and costimulatory
molecules [28]. The enriched CSCs also showed increased expres-
sion of lysyl oxidase (LOX) and a CSC marker, alcohol dehydroge-
nase (ALDH), whereas a LOX inhibitor suppressed the growth of the
tumors passaged in immunocompetent mice [28]. Consistently,
tumor tissues exposed to an immune challenge in vivo exhibited a
CSC-like gene expression profile with increased CSC properties,
including tumor initiation ability [29]. These results suggest that
tumor immunity preferentially kills non-CSCs, leading to an in-
crease in CSCs, although it is also worth investigating whether tu-
mor immunity induces CSC properties in non-CSCs.
The immune evasion property, the tumor initiation ability in the
presence of immune surveillance, is an additional characteristic of
CSCs [30]. Thus, tumor-initiating cells investigated in highly
immunocompromised animals would underestimate the true22frequency of CSCs present in a tumor tissue [31]. As such, studies
examining the in vivo function of CSCs should be performed with
partially immunocompromised, syngeneic, or congenic immuno-
competent animals [32]. For example, transplantation of hemato-
poietic stem cells transduced with the ovalbumin and MLL/AF9
fusion genes, in which the latter causes acute myeloid leukemia
(AML), into wild-type mice resulted in the development of leuke-
mia although ovalbumin-specific CTLs had expanded in the trans-
planted mice [33]. Interestingly, this syngeneic transplantation
model revealed that the cancer cells exhibited high expression of
immune checkpoint molecules, such as PD-1 and lymphocyte
activation gene 3 (LAG3) (Table 1) [33]. These results indicate that
an immunocompetent mouse represents a good model for the
investigation of the immunological features of CSCs.3. Immunosuppressive properties endowed on CSCs
It has been shown that the expression of CSC makers in human
tumor tissues is correlated with the number of tumor-infiltrating
immune cells [34,35], suggesting that CSCs exhibit a close rela-
tionship with the tumor immune environment. Accumulating
evidence suggests that the immune response to CSCs is frequently
compromised because of their immune evasion properties.
For example, CSCs may secrete immunosuppressive factors and
recruit immunosuppressive noncancerous cells. Subsequently, the
immune suppressive cells, in turn, induce and maintain CSCs.
However, the dynamics of the tumor microenvironment are
complicated, and mechanisms that create the immunosuppressive
milieu can vary depending on tumor development. In this section,
we summarize the immunosuppressive mechanisms harnessed by
CSCs.
3.1. Impaired antigen presentation of CSCs
The interaction between the T-cell receptor (TCR) on CTLs with
MHC-I antigens is a prerequisite for a proper T-cell response against
tumor cells. Antigens must be sufficiently degraded by
Table 1
Regulation of effector T cells by molecules on tumor cells.
Tumor cells Effector T cells Effector function Function in CSCs
MHC class I & II TCR activation [37e41,43,44,48e50,132,133]




CD274/PD-L1/B7eH1 CD279/PD-1 inhibition [130,141,143,151e163,166,167,169]
CD273/PD-L2/B7-DC
CD275/ICOS-L/B7eH2 CD278/ICOS/AILIM activation ?
CD276/B7eH3 ? ? ?
VTCN1/B7eS1/B7eH4 ? ? ?
VISTA/GI24/B7eH5 CD28H/IGPR1/TMIGD2 inhibition? ?
HHLA2/B7eH7
NCR3LG1/B7eH6 CD337/NKp30/NCR3a activation [78e80]
MHC class II CD223/LAG3 activation [33,186,187]
FGL1, galectin-3, LSECtin inhibition
CEACAM1, galectin-9, HMGB1 TIM3 inhibition ?
CD200 CD200R inhibition [179e182]
AILIM, activation-inducible lymphocyte immunomodulatory molecule; CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; CTLA-4, cytotoxic T-cell-
associated antigen-4; FGL1, fibrinogen-like protein 1; HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; HMGB1, high-mobility group box-
1; ICOS, inducible T-cell co-stimulator; ICOS-L, ICOS ligand; IGPR1, immunoglobulin and proline-rich receptor-1; LAG3, lymphocyte activation gene 3; LSECtin, liver and lymph
node sinusoidal endothelial cell C-type lectin; MHC, major histocompatibility complex; NCR3, natural cytotoxicity triggering receptor 3; NCR3LG1, NCR3 ligand 1; PD-1,
programmed cell death-1; PD-L1/2, PD-1 ligand 1/2; TCR, T-cell receptor; TIM3, T-cell immunoglobulin and mucin domain 3; TMIGD2, transmembrane and immunoglob-
ulin domain containing 2; VISTA, V-domain immunoglobulin suppressor of T-cell activation; VTCN1, V-set domain-containing T-cell activation inhibitor 1.
a Expressed on NK cells.
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porter proteins, and presented by MHC-I molecules. Otherwise, T
cells fail to recognize transformed cells. It has been suggested that
these antigen processing and presenting steps are impaired in CSCs.
Cancer cells cultured in an ultralow attachment dish form
spheroids enriched with CSCs because CSCs exhibit an anchorage-
independent growth [36]. Melanoma spheroids also show
increased CSC properties compared with adherent cells [37]. MHC
molecules are shown to be downregulated in melanoma spheroid
cells, leading to the inhibition of the allogenic immune response of
T cells [37]. Likewise, defects in MHC-I-mediated antigen presen-
tation are often observed in CSCs and render the cells resistant to
the cytotoxic effects of CTL [38]. A similar observation has also been
reported in normal hematopoietic cells and Lgr5þ normal epithe-
lial stem cells [39,40], suggesting that impaired antigen presenta-
tion may be a common feature of stem cells.
Neurospheres produced from primary glioblastoma were also
enriched in glioblastoma CSCs, which exhibited low MHC-I
expression levels and lacked MHC-II expression. Moreover, neuro-
sphere cells also showed downregulation of antigen-processing
molecules, including low-molecular-weight protein (LMP), trans-
porter associated with antigen processing (TAP), and beta-
macroglobulin [41], suggesting that not only antigen presentation
but also antigen processing is impaired in glioblastoma CSCs.
Consistently, T-cell activation and proliferation was more signifi-
cantly impaired by these CSCs compared with non-CSCs [41,42]. It
was shown that IFNs, which are potent immune modulatory cyto-
kines, induced the expression of MHC-I molecules in glioblastoma
CSCs. However, the expression level of MHC-I molecules in CSCs
treated with IFNs was still lower compared with that in non-CSCs
[41]. This suggests that an IFN response suppression mechanism
plays a role in the immune evasion property of glioblastoma CSCs.
It was demonstrated that CSCs derived from head and neck
squamous cell carcinoma (HNSCC) also exhibit downregulation of
MHC molecules [43,44]. CD44þ HNSCC cells exhibited CSC prop-
erties and downregulated HLA-A2, HLA class II, and TAP2, sug-
gesting the impairment of antigen presentation and processing
such as glioblastoma CSCs [43]. Moreover, in addition to the sup-
pression of the Th1 response, CD44þ HNSCC cells also induced
regulatory T (Treg) cells and MDSCs concomitant with high
expression of immune modulatory cytokines, including IL-8,23granulocyte colony-stimulating factor, and TGFb [43]. HNSCC
spheroid cells, as observed in CD44þ HNSCC cells, also exhibited
low expression of MHC-I and resistance to CTLs [44]. However, IFNg
efficiently induced MHC-I expression in spheroid cells and sensi-
tized the cells to CTL-mediated cytolysis [44]. Interestingly,
ALDHlow HNSCC spheroid cells were more susceptible to CTLs in the
presence of IFNg than ALDHlow spheroid cells [44].
In contrast, mouse breast ALDHþ CSCs efficiently formed tumors
in immunocompetent mice, whereas the growth of bulk cells
containing CSCs and non-CSCs was limited [45]. The ALDHþ CSCs
downregulated the expression of TAP genes and a costimulatory
molecule, CD80 (B7-1), by DNA methylation (Table 1) [45]. How-
ever, CD44þ/CD24 CSCs in murine breast cancer did not show
decreased TAP and CD80 expression and upregulated C-X-C motif
chemokine receptor 4, which is involved in the induction of the CSC
and EMT phenotypes in breast cancer [45,46]. It is not surprising
that themechanisms underlying the immunemodulatory functions
may vary among CSCs expressing different CSC markers, because
some of these markers exhibit distinct functions in regulating
CSCs [47].
Spheroid cells derived from TC-1 cells, a lung cancer cell line
transduced with viral oncogene E6/E7, showed lower MHC-I
expression compared with adherent cells [48]. IFNg sensitized
spheroid cells to E6/E7-specific immune attack by inducing MHC-I
expression [48]. In contrast, the spheroid cells derived from 12 solid
tumor cell lines (colon, pancreas, melanoma, and breast cancer)
exhibited higher expression of antigen processing and presentation
molecules, including LMP2/LMP7, MECL1, and TAP1/TAP2, whereas
the expression levels of HLA-I and HLA-II were lower compared
with those in adherent cells [49], suggesting that T-cell activation
by the spheroid cells may be impaired. However, IFNg failed to
induce the expression of HLA molecules in spheroid cells [49].
Therefore, the sensitivity of CSCs to IFNg differs among cell lines. In
addition, mechanisms responsible for the regulation of antigen
presentation and antigen-processing molecules in CSCs may also
differ. The expression of MHC-I molecules was found to be tran-
scriptionally downregulated in glioblastoma [50], whereas, in pe-
ripheral blood mononuclear cells, a serine protease, cathepsin G,
degraded MHC-I molecules in the endosome and lysosome [51].
Although active cathepsin G is not present in glioblastoma cells
H. Tsuchiya and G. Shiota Regenerative Therapy 17 (2021) 20e33[51], CSCs may utilize multiple pathways to downregulate MHC-I
expression at the transcriptional and posttranscriptional levels.
3.2. Downregulation of tumor-associated antigens in CSCs
As observed in NOD/SCID and NSG mice, the melanoma initia-
tion property depends on host immunity, and only CSCs can evade
immune surveillance to form tumors in NOD/SCID mice [17,52]. In
addition to the downregulation of MHC-I and MHC-II molecules,
melanoma CSCs evade tumor immune surveillance through several
mechanisms, one of which involves the downregulation of
melanoma-associated antigens [53,54]. Consequently, T cells failed
to efficiently recognize melanoma CSCs; however, CSCs highly ex-
press the marker proteins specific for CSCs, which are necessary for
CSC induction and maintenance [47]. Therefore, CSC-specific pro-
teins are desirable targets as tumor-associated antigens for cancer
immune therapy. Consistently, it was demonstrated that activating
the immune response to octamer-binding transcription factor 4
(OCT4), which is a well-known stemness transcription factor, sup-
pressed the growth of teratoma cells in mice [55]. Intriguingly, it
was reported that naturally occurring T cells specific for OCT4 were
found in the ascites and peripheral blood of patients with ovarian
cancer, although they lost the ability to eliminate OCT4þ CSCs
[56,57]. However, these OCT4-specific T cells were activated by DCs
primed with an OCT4-derived peptide [57].
Antibodies against another stemness transcription factor, sex-
determining region Y- box 2 (SOX2), were also found in the
serum of patients with lung cancer, prostate cancer, and glioblas-
toma [58,59]. The presence of SOX2-reactive antibodies predicted a
good prognosis in patients with lung cancer [58]. SOX2-reactive T
cells were also found in patients with monoclonal gammopathy, a
benign disease, that sporadically progresses to multiple myeloma
[60]. However, the SOX2-reactive T cells disappeared in patients
with myeloma [60], suggesting that the collapse of anti-SOX2 im-
munity may be a mechanism of progression to multiple myeloma.
It has been clinically and experimentally demonstrated that
immunotherapy targeting CSCmarkers, such as CD133 [61,62], CD44
[63,64], CD24 [65], and EPCAM [66,67], can suppress tumor growth.
However, these CSC markers are also expressed in normal cells.
Therefore, embryonic stemness markers, such as OCT4 and SOX2,
may be preferential targets for CSC-specific immunotherapy [68].
3.3. Modulation of NK-cell activity by CSCs
In general, it is known that NK cells attack “missing self” cells
exhibiting a lack or low expression of MHC-I. This antigen-
presenting molecule suppresses NK activity by interacting with
NK-cell inhibitory receptors on the surface of NK cells (Fig. 2) [69].
The preferential targeting of NK cells suggests that, although CSCs
could escape fromMHC-restricted T-cell recognition, theywould be
eventually eliminated by NK cells. Nonetheless, the sensitivity of
CSCs to NK-cell-mediated cell lysis remains under debate because
CSCs, not non-CSCs, can form tumors in NOD/SCID mice [16]. This
indicates that the tumor microenvironment containing immuno-
suppressive noncancerous cells should also be considered to in-
crease our understanding of the relationship between CSCs and NK
cells [70]. However, because of space limitations, only the intrinsic
properties of CSCs are discussed in the following sections.
3.4. NK cell-sensitive phenotype of CSCs
It has been demonstrated that NK-cell-mediated cell lysis ac-
tivity is enhanced by coculture with CSCs [71,72]. Consistently, NK
cells preferentially killed CD24þ/CD44þ, CD133þ, and ALDHhigh CSC
lines and primary tumors in vitro [73]. In addition to24downregulating MHC-I, NK cells may preferentially kill CSCs
because of the upregulation of NK-cell-activating receptor ligands
in CSCs (Fig. 2). Furthermore, it was revealed that CSCs exhibited
high expression of MHC-I polypeptide-related sequence A/B (MICA/
MICB; ligands for a NK-cell-activating receptor, NKG2D) and were
killed by NK cells in a manner depending on NKG2D [73].
In addition, NK cells utilize not only the secretory granule-
mediated cell lysis pathway involving perforin and granzymes
but also the FAS/FASL and DR4/DR5/TRAIL death receptor pathways
to kill tumor cells [74]. CSCs from a colon cancer cell line showed c-
MYC-mediated expression of DR4 and were susceptible to TRAIL-
induced apoptosis [75]. Breast CD44þ/CD24/low CSCs isolated
from a spontaneous breast carcinogenesis model (B6 PyMT-MMTV
transgenic mouse) expressed FAS and DR5 and were more
susceptible to FASL- and TRAIL-induced apoptosis compared with
non-CSCs [76]. Although these CSCs exhibited lower expression of
MHC-I and higher expression of Rae-1 (NKG2D ligand) and CD155/
PVR (ligand for a NK-cell-activating receptor, DNAM-1) compared
with non-CSCs, the sensitivity to NK-cell-mediated cell lysis was
not significantly different between the CSCs and non-CSCs [76].
Therefore, these results suggest that the sensitivity of CSCs to NK
cells may not be determined by these cell surface molecules. It is
noted that cancer cells are prone to be resistant against the death
receptor pathways by modulating the expression of proapoptotic
and antiapoptotic regulators [77].
Nonetheless, it has been suggested that various ligands for NK-
cell-activating receptors are involved in the sensitization of CSCs to
NK cells. Colon CSCs displayed reduced MHC-I expression and
upregulation of CSC markers (CD133, CD44, Lgr5, and CD166) and
ligands for the NK-cell-activating receptors, NKp30 and NKp44. As a
result, they were more sensitive to allogenic NK-cell-mediated cell
lysis compared with non-CSCs [78]. Ovarian CD24þ CSCs also
exhibited downregulation of MHC-I molecules and upregulation of
NKG2D ligands compared with non-CSCs [71]. Similarly, ovarian
CSCs were more susceptible to NK-cell-mediated lysis compared
with non-CSCs [71]. In patient-derived melanoma cell lines, it was
found that a subpopulation of CeC motif chemokine receptor 7
(CCR7)-positive cells exhibited certain CSC characteristics,
including sphere formation, tumorigenesis, metastatic potential,
and CSC marker expression [79]. These CCR7-positive melanoma
CSCs also exhibited reduced MHC-I molecule and CD155/PVR
expression, but upregulation of ligands for NKp30 and NKp46 [79].
Consistently, allogenic NK cells more efficiently lysed CCR7-positive
CSCs compared with non-CSCs, although CCR7-positive CSCs also
displayed higher expression of the two immune checkpoint ligands
PD-L1 and galectin-9 [79]. As a result of NKp30 ligand expression
(NKp46, DNAM-1, and NKG2D), medulloblastoma cells were sen-
sitive to NK-cell-mediated cell lysis, regardless of their CD133
expression status [80]. Further investigation on the expression of
NK-cell-activating receptor ligands in CSCs may benefit the devel-
opment of NK-cell-based immunotherapy.
It was demonstrated that glioblastoma CSCs were more sensi-
tive to NK-cell-mediated cytotoxicity compared with non-CSCs
because of the higher expression of NKG2D ligands including
UL16 binding protein 1 (ULBP1) and ULBP3 [81]. In contrast,
another report [82] showed that glioblastoma CSCs were resistant
to NK cells. However, when NK cells were activated by lectin and IL-
2, these CSCs were more efficiently killed by the NK cells compared
with non-CSCs [82]. Primary cancer cells isolated from nine pa-
tients with glioblastoma expressed neuronal stem cell markers and
exhibited amulti-lineage differentiation potential when cultured in
a stem cell medium [83]. Glioblastoma CSCs derived from all pa-
tients expressed HLA-I molecules (A, B, C) and HLA-E, which sup-
pressed the activation and function of NK cells through killer
immunoglobulin-like receptors (KIRs) and the NKG2A receptor,
Fig. 2. Pathways for the recognition and killing of cancer cells by NK cells. Details are discussed in the main text.
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DNAM-1 ligands, CD155/PVR and CD112/Nectin-2, and showed low,
but detectable, expression of one of the NKG2D ligands (MICA/MICB
and ULBPs) [83]. Consistently, allogenic and autologous NK cells
activated by IL-2 or IL-15 efficiently lysed these glioma CSCs [83].
As described in this section, NK-cell-based immunotherapy is
expected to efficiently eliminate CSCs [85]. These NK cells need to
be activated by cytokines to exhibit complete NK activity. Inevi-
tably, cytokine-induced killer cells (CIKs) attract attention for im-
mune cell therapy targeting CSCs. CIKs are induced from peripheral
blood mononuclear cells following treatment with specific cyto-
kines, such as IL-2 and IFNg [86]. Accordingly, CIKs are a mixture of
CD3/CD56þ NK cells, CD3þ/CD56 T cells, and CD3þ/CD56þ bona
fide CIKs [86]. CD3þ/CD56þ CIKs express the NK-activating receptor,
NKG2D, and exhibit MHC-unrestricted cytotoxicity against a wide
variety of malignant cells, possibly through NKG2D, but not toward
normal cells [86]. CIKs were shown to kill osteosarcoma CSCs
without enriching CSCs [87]. CIKs were also shown to directly lyse
nasopharyngeal CSCs in an NKG2D-dependent manner and prolong
survival in patients with nasopharyngeal carcinoma treated with
gemcitabine and cisplatin [88,89]. Moreover, CIKs combined with
DCs also demonstrated significant therapeutic effects on patients
with metastatic breast cancer, advanced colorectal cancer, and
metastatic renal cell carcinoma [90e92]. CIK-mediated cytotoxicity
against CSCs was also experimentally demonstrated in lymphoma
[93], melanoma [94,95], and hepatocellular carcinoma [96].3.5. NK-cell-resistant phenotype of CSCs
As described above, many CSCs exhibit downregulation of MHC-
I molecules and upregulation of NK-cell-activating receptor ligands.
They are susceptible to NK-cell-mediated cell lysis and, in some25cases, more compared with non-CSCs. However, the fact that CSCs,
not non-CSCs, can initiate tumor formation in NOD/SCID mice in
which NK activity is low but detectable [16] indicates that tumor-
initiating cells have an immune evasion ability, in particular, from
NK cells. Hereafter, we present studies demonstrating the ability of
CSCs to evade NK-cell surveillance.
It has been shown that adult T-cell leukemia downregulates
NKG2D ligands, concomitant with increased expression of CD44
and the EMT marker, vimentin, and acquires an apoptosis-resistant
phenotype [97]. Glioblastoma CSCs also downregulate NK-cell-
activating receptor ligands, including MICA/MICB and ULBPs, and
are resistant to NK-cell-mediated cytotoxicity [41]. Downregulation
of NK-cell-activating receptor ligands was also observed in colon
cancer cells with activated STAT3, a transcription factor that regu-
lates colon CSCs [98,99]. STAT3 suppression in colon cancer cells
induced MICA expression, which enhanced NK-cell activation [99],
suggesting that STAT3 confers not only CSC properties but also NK-
cell resistance.
CSCs may upregulate MHC-I molecules to acquire NK-cell
resistance. It was shown that EPCAMþ/CD45þ ascitic cells in pa-
tients with epithelial ovarian carcinoma possessed CSC properties,
including drug resistance, high metastatic potential, and high CSC
marker expression [100]. These cells also upregulated MHC-I mol-
ecules and exhibited resistance to NK-cell-mediated cell lysis by
suppressing the activation of CD3/CD56þ NK cells, whereas
EPCAM single-positive cells were efficiently lysed by NK cells [100].
Another study reported that spheroid cells derived from a renal
carcinoma cell line exhibited higher tumorigenicity and increased
expression of stemness factors, including OCT4, NANOG, and BMI,
comparedwithmonolayer cells [101]. In these spheroid cells, MHC-
I molecules were also significantly expressed, whereas NK-cell-
activating receptor ligands were downregulated compared with
H. Tsuchiya and G. Shiota Regenerative Therapy 17 (2021) 20e33monolayer cells. This suggests that these renal CSCs are less sen-
sitive to NK-cell-mediated cell lysis [101].
HLA-G and HLA-E are nonclassical MHC-I molecules that may be
involved in the underlying immune evasion mechanism of cancer
cells fromNK-cell surveillance [84,102,103]. KIR2DL4 and NKG2A on
the surface of NK cells represent HLA-G- and HLA-E-specific re-
ceptors, respectively (Fig. 2), and provide an inhibitory signal to NK
cells upon ligand binding [104]. In colorectal carcinoma tissues, the
expression of HLA-G, HLA-E, and CSC markers was significantly
higher compared with noncancerous colorectal tissues [105]. This
suggests that HLA-G and HLA-E are involved in immune evasion of
colorectal CSCs from NK-cell surveillance. Another study demon-
strated that HLA-E was expressed in CSCs from patient-derived
glioblastoma cell lines, although the expression levels were
different among individual cell lines [106]. In contrast, under dif-
ferentiation culture conditions, HLA-E expression was down-
regulated in some glioblastoma cell lines [106]. Consistently, the
differentiated glioblastoma cells exhibited increased sensitivity to
NK-cell-mediated cell lysis. Knockdown of HLA-E sensitized the
glioblastoma cells to NK cells regardless of CD133 status [106],
suggesting that HLA-E contributes to immune evasion in glioblas-
toma. Notably, stimulation with IFNg induced HLA-E expression in
all glioblastoma CSCs [106]. However, it has also been suggested
that IFNg enhances the immunogenicity of CSCs by upregulating
MHC-I molecules [48]. Therefore, these results suggest that HLA-E
is an important factor for glioblastoma CSCs to survive immune
selection. Interestingly, HLA-G regulates the cell surface localiza-
tion of HLA-E and thereby indirectly inhibits NK-cell activation
[107]. HLA-G also has additional effects against DCs. CD105-positive
renal CSCs exhibited increased expression of HLA-G, which was
delivered to DCs by extracellular vesicles (EVs) [108]. Consistently,
the EVs secreted by these CSCs inhibited the maturation of DCs
more significantly compared with those secreted by CD105-
negative non-CSCs [108]. In contrast to human HLA-G, the murine
homolog, Qa-2, has been reported to be an immunogenic molecule
and contribute to tumor rejection [109]. In murine CD44þ/CD24
breast CSCs, Qa-2 expression was abrogated, possibly by the Src
signaling pathway, whereas Src inhibitor treatment suppressed the
CSC properties of breast cancer cells and restored Qa-2 expression
[110]. Moreover, Qa-2 overexpression suppressed breast cancer
growth and metastasis [110]. Therefore, caution is needed when
interpreting the Qa-2 and HLA-G data obtained from mouse
studies.
3.6. Inhibition of cytolytic granules by CSCs
Upon recognition of target cells, CTL and NK cells release cyto-
lytic granules that contain perforin and granzymes (Fig. 2). Perforin
oligomerizes and forms pores in the membranes of target cells. At
high concentrations, perforin induces necrosis because of a loss of
membrane integrity, whereas perforin at low concentrations in-
duces apoptosis in a granzyme-dependent manner, which are
delivered to the cytosol through perforin-formed pores or by
perforin-triggered endocytosis [111]. Granzymes are serine pro-
teases that activate pro-caspases and cleave various nuclear and
mitochondrial proteins [112]. CSCs deploy several strategies to
inhibit these cytolytic molecules. In spheroids of an estrogen re-
ceptor-a-positive breast cancer cell line, protease inhibitor 9 (PI9), a
potent granzyme B inhibitor, was shown to be upregulated [113].
Estrogen enhanced spheroid formation and increased PI9 expres-
sion in the cells [113]. These results suggest that breast CSCs acquire
resistance to CTL- and NK-cell-mediated cell lysis by PI9.
Serglycin, a proteoglycan with high affinity for granzyme B,
contributes to the stabilization of granzyme B in lytic granules and
delivery to target cells. Internalization of granzyme B into target26cells requires an electrostatic exchange from serglycin to cell sur-
face proteoglycans [114]. Mast cells infiltrated into glioma tissues
induced serglycin expression, as well as CD44 and ZEB1, CSC and
EMT markers, respectively [115]. Moreover, serglycin expression in
glioma tissues was significantly associated with poor prognosis
[115]. These results suggest that mast cell-induced serglycin con-
tributes to the immune evasion of glioma CSCs from CTL and NK
cells. However, multiple functions of serglycin [116] suggest that
other mechanisms may also be involved in the malignant function
of serglycin.
Watanabe et al. found that calreticulin was upregulated on the
cell surface of pancreatic CSCs and that the expression of calreti-
culin was significantly associated with poor prognosis in patients
with pancreatic cancer [117]. Calreticulin is a chaperone protein
present in cytolytic granules of CTL and NK cells to prevent the
unnecessary activation of perforin [118,119]. Accordingly, pancre-
atic CSCs may escape perforin-mediated cytolysis by expressing
calreticulin. However, calreticulin also appears on the cell surface of
apoptotic cells by binding to phosphatidylserine and promotes
phagocytosis as an “eat-me signal” [120,121]. Therefore, further
studies are necessary to clarify the precise role of calcineurin in CSC.
3.7. Humoral factors modulating immune response to CSCs
A number of humoral factors are involved in the regulation of
immune response, which is also the case with immune evasion by
CSCs. Such immunomodulatory factors are secreted not only by
CSCs but also by tumor-associated noncancerous cells. In this sec-
tion, we nonetheless summarized the factors that are secreted by
CSCs or directly influence the immune evasion property of CSCs.
TGFb is a multifunctional cytokine that induces CSCs and im-
mune suppression, as well as EMT [122,123]. CD44þ/CD24 breast
CSCs were found to secrete a higher level of TGFb compared with
non-CSCs. In these CSCs, activation of the TGFb signaling pathway
was observed [124,125]. Consequently, TGFb induced an EMT
phenotype and enhanced stemness in not only breast cancer cells
but also in normal mammary epithelial cells [126e128]. In contrast,
metformin suppressed the TGFb-induced EMT phenotype, self-
renewal, and proliferation of trastuzumab-resistant breast CSCs
[127,128]. In breast CSCs, the Sca-1 stem cell marker was suggested
to be involved in TGFb signaling [129]. It was shown that the human
Sca-1 homologs Ly6K and Ly6E play an important role in TGFb-
induced SMAD2/SMAD3 activation, induced immune evasion, and
eventually were associated with poor prognosis in patients with
breast cancer [130]. In glioma CSCs, another CSC marker, CD133,
was suggested to be involved in TGFb production since CD133þ
glioma CSCs exhibited higher expression of TGFb compared with
CD133 glioma CSCs [129]. Cytomegalovirus (CMV), with which
glioma cells are frequently infected, is also suggested to be involved
in TGFb production in glioma. Interestingly, CMV-infected glioma
CSCs secreted CMV IL-10 encoded by the CMV genome, induced
immunosuppressive M2 macrophages, and enhanced the produc-
tion of TGFb by monocytes [131]. The CSC- or monocyte-induced
TGFb, in turn, downregulated NKG2D and MHC-II molecules in
glioblastoma cells [132,133]. In addition, TGFb secreted from glio-
blastoma CSCs induced the differentiation of Tregs from naïve T
cells [42], enabling the escape of glioblastoma CSCs from immune
recognition. Meanwhile, retinoic acid-inducible gene I (RIG-I) ex-
hibits suppressive effects on virus infection and CSC induction.
Consistently, RIG-I knockdown increased CSC marker expression in
hepatocellular carcinoma [134]. These hepatic CSCs secreted TGFb
to enhance hepatic CSC properties through the SMAD2/AKT
pathway in an autocrine manner [134]. TGFb further inhibited the
differentiation and maturation of DCs and recruited immature DCs
with decreased expression of costimulatory molecules to
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involving urokinase-type plasminogen activator receptor (uPAR)
was proposed for TGFb production in CSCs. In breast cancer, uPAR
increased the CD44þ/CD24 CSC population with upregulation of a
breast CSC marker, integrin a1b6, and enhanced tumor initiation
[135]. The expression of uPAR was found in breast cancer, pancre-
atic cancer, and glioblastoma and was associated with the secretion
of TGFb and IL-4 [136]. These immunosuppressive cytokines
induced the differentiation of macrophages into an arginase 1-
positive M2 phenotype and thereby created an immunosuppres-
sive tumor microenvironment [136]. These results suggest that
TGFb is not only a direct target of cancer therapy but also enhances
tumor immunity. Other TGFb familymembers, such as activin A and
nodal, secreted by CSCs in pancreatic adenocarcinoma promoted
cathelicidin-18 secretion from TAMs [137]. Cathelicidin-18, in turn,
enhanced CSC function by binding to the formyl peptide receptor 2
and P2X purinoceptor 7 purinergic receptor [137]. The fact that
TGFb and nodal/activins share SMAD2/SMAD3 as downstream ef-
fectors renders these signaling molecules attractive targets for
cancer therapy.
IL-6 is a pleiotropic cytokine that also plays an important role in
the induction of CSCs. In lung cancer, IL-6 upregulated the
expression of DNA methyltransferase (DNMT) 1 through JAK2/
STAT3 signaling. This subsequently silenced transcription of cell
cycle regulatory factors and thereby induced lung CSCs [138]. IL-6
secreted by TAMs was shown to induce and maintain CSC proper-
ties through STAT3 in breast cancer [139]. C/EBPd also mediated IL-
6- and hypoxia-induced breast CSCs by activating the NOTCH1
pathway [140]. In prostate cancer, IL-6 induced CD44þ CSCs in an
autocrinemanner [141]. IL-6 and CD44 expressionwas significantly
associated with tumor malignancy and poor prognosis [141]. IL-6
also upregulated PD-L1 expression in CD44þ CSCs and recruited
MDSCs to tumors and suppressed tumor infiltration of T cells [141].
Inhibition of the IL-6/STAT3 pathway resulted in the down-
regulation of PD-L1 and CD44 expression, decreased CSC proper-
ties, and suppressed tumor growth [141]. STAT3 is a transcription
factor required for the maintenance of pluripotency in stem cells
and plays an important role in the maintenance and induction of
CSCs in both IL-6-dependent and IL-6-independent manners. In
bladder CSCs, histone 3 K9 trimethylation by KMT1A upregulated
STAT3 expression in an IL-6-independent manner by suppressing
GATA3, which suppressed STAT3 transcription [142]. Consistently,
deletion of the KMT1A gene decreased CSC properties in bladder
cancer [142]. CD44þ CSCs of HNSCC exhibited constitutive activa-
tion of STAT3, which upregulated PD-L1 expression [143]. These
results suggest that IL-6- or STAT3-targeting therapy will benefit
patients with malignant tumors.
CCL20 is also implicated in the immune evasion of CSCs. Breast
cancer cells induced CSC properties by secreting CCL20, which
activated NFkB via PKCz and p38MAPK [144]. NFkB, in turn, induced
CCL20 transcription by forming a positive feedback loop [144].
CCL20 and its receptor, the CCR6 axis, may recruit Tregs to tumors
of hepatocellular, esophageal, and squamous cell and lung cancers
to promote tumor progression, metastasis, drug resistance, and
poor prognosis as a consequence of enhanced immune evasion
[145e148].3.8. Expression of immunosuppressive molecules in CSCs
3.8.1. PD-L1
It has been demonstrated that cancer cells also employ immune
checkpoint molecules while downregulating costimulatory mole-
cules to suppress tumor immunity (Table 1) [149]. PD-L1 expres-
sion has been frequently observed in tumor cells. Upon binding to27PD-1 on immune cells, PD-L1 suppresses their effector functions,
and induces their exhaustion [150].
PD-L1 was found to be expressed in patient-derived Lgr5þ
gastric CSCs, and its expression in gastric CSCs was associated with
tumor growth [151]. In breast cancer and malignant mesothelioma,
PD-L1 expression was positively correlated with CSC marker
expression [152,153]. Epithelial CSCs derived from the ascites of
patients with bladder cancer also exhibited PD-L1 expression as
well as E-cadherin, CD24, and VEGFR2, and had more potent
tumorigenicity compared with mesenchymal CSCs that exhibited
constitutively active TGFb signaling [154]. An ALDH isozyme,
ALDH3A1, was shown to increase CSC properties, EMT, and the
expression of pro-inflammatory factors in non-small cell lung
cancer and melanoma and was significantly correlated with PD-L1
expression [155]. Moreover, ALDH3A1 overexpression also upre-
gulated PD-L1 expression, which inhibited the proliferation of pe-
ripheral immune cells [155]. It was demonstrated that the
population of CD44þ/CD133þ CSCs was higher in PD-L1high
pancreatic tumors comparedwith PD-L1low tumors [156]. However,
higher infiltration of CD8þ T cells was associated with a favorable
prognosis for patients evenwith PD-L1high pancreatic tumors [156].
These observations suggest that CSCs clinically correlate with PD-
L1 expression and rationalize the activation of T cells by immune
checkpoint inhibitors to overcome the PD-L1-mediated immune
checkpoint pathway.
It has been suggested that several factors are involved in PD-L1
expression in CSCs, although further studies are necessary. In breast
cancer cells, it was determined that Ly6K/E were required for not
only TGFb-induced SMAD activation but also IL-4-induced PD-L1
expression [130]. Consistently, PD-L1 expression was significantly
correlated with Ly6K/E [130]. Notably, proteasome activator sub-
unit 3 (PSME3) was suggested to be involved in breast CSCs [157].
PSME3 overexpression upregulated PD-L1 expression, as well as
EMT and CSC markers, leading to the suppression of chemotaxis of
CD8þ T cells and the induction of T-cell apoptosis [157]. Conversely,
PSME3 knockdown downregulated PD-L1 expression, promoted
CD8þ T-cell activation, and suppressed tumor growth [157]. On the
other hand, in ALDH1þ-radioresistant CSCs of oral squamous cell
carcinoma, PD-L1 and DNMT3B expression was positively corre-
lated and associated with increased MDSC infiltration into tumors
[158]. Interestingly, pharmacological inhibition of DNMT3B
downregulated PD-L1 expression, impaired the radioresistance of
ALDH1þ cells, and suppressed MDSC infiltration [158]. In CD133þ/
CD44þ colorectal CSCs and drug-resistant colorectal cancer cells,
increased PD-L1 expression was observed [159]. Moreover, PD-L1
increased CSC properties and expanded the CSC population in
colorectal cancer cells through the PI3K/AKT and MEK/ERK path-
ways that were activated by direct interaction of PD-L1 with
HMGA1 [159]. Another report showed that the AT-rich interaction
domain-containing protein 3B (ARID3B) recruited lysine-specific
demethylase 4C (KDM4C) to chromatin in colorectal cancer,
which subsequently induced the expression of NOTCH-target
genes, intestinal stem genes, and PD-L1 [160]. Conversely, a
KDM4C inhibitor decreased ARID3B-induced CSC properties and
PD-L1 expression [160]. Insulin induced PD-L1 expression through
the PI3K/AKT/mTOR pathway in colon CSCs [161]. Interestingly, EGF
promoted the transfer of PD-L1 protein to the cell membrane,
although it did not affect PD-L1 expression in colon CSCs [161]. On
the contrary, in AML, STAT3 was also suggested to play a role in PD-
L1 expression since STAT3 knockdown downregulated PD-L1
expression [162]. Consistently, STAT3 knockdown in combination
with toll-like receptor 9 activation resulted in the activation of
tumor immunity [162]. In thyroid CSCs, acetylcholine secreted by
tumor-invading neurons also increased CSC properties and PD-L1
expression through the CD133/PI3K/AKT pathway, whereas an
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erties and PD-L1 expression [163]. These results suggest that the
mechanisms underlying PD-L1 expression in CSCs represent novel
targets to improve the therapeutic efficacy of immune checkpoint
inhibitors.
3.8.2. IFNs
IFNs are potent antiviral and antineoplastic cytokines. However,
in a mouse model of chronic virus infection, the blockade of the
type-I IFN pathway downregulated the immunosuppressive factors
IL-10 and PD-L1 and resulted in a substantial reduction in viral ti-
ters in the infected animals [164,165]. This dual role of IFNs
(immunostimulative or immunosuppressive) may, in part, depend
on a period of IFN exposure time (acute phase or chronic phase)
[164,165]. In tumors, it was shown that PD-L1 expression was
induced by IFNg secreted from activated Tand NK cells in a negative
feedback manner [166]. Moreover, IFNg also induced PD-L1
expression in CD44þ CSCs of HNSCC, possibly through STAT1
[143]. In melanoma, IFNg also upregulated the expression of
CD271/NGFR and PD-L1 and thereby increased CSC properties via
NGF stimulation [167]. Interestingly, avelumab is a fully humanized
anti-PD-L1 IgG1 capable of inducing ADCC in addition to inhibiting
the PD-1/PD-L1 pathway [168]. The PD-L1 expression in chordoma
cells was upregulated by coculture with CD8þ T cells, leading to
further enhancement of avelumab-induced ADCC [168]. Therefore,
the clarification of the precise mechanisms of IFNg-induced PD-L1
expression in CSCs may provide further improvement in PD-1-/
PD-L1-targeted cancer therapy.
IFNs are also involved in CSC induction and maintenance [167].
In methylcholanthrene-induced sarcoma in mice, treatment with
anti-PD-L1 or anti-CTLA-4 antibodies expanded the Sca-1þ/CD90
CSC population, suggesting that an alternative immune evasion
mechanismmay be employed by the CSCs [169]. IFNg is involved in
the expansion of the Sca-1þ/CD90 CSC population in
methylcholanthrene-induced sarcoma because IFNg blockade
decreased its expansion [169]. On the other hand, IFNa upregulated
the expression of CSC markers and induced the EMT phenotype in
pancreatic adenocarcinoma [170]. Moreover, IFNb secreted from
pancreatic adenocarcinoma cells induced TAMs to produce IFN-
stimulated gene 15, which subsequently promoted the induction
and maintenance of pancreatic adenocarcinoma CSCs [171]. The
underlying mechanism of IFN-induced CSC properties may be
dependent, at least in part, on its concentration. Thus, IFNg at low
concentrations induced CSC properties in non-small cell lung
cancer through the ICAM1/PI3K/AKT/NOTCH1 pathway, whereas it
induced apoptosis through the JAK1/STAT1/caspase pathway at
high concentrations [172].
IFNs inhibit the tumor-initiating property and expansion of CSCs
[173], and the response to IFNs was suppressed in CSCs to resist the
anti-neoplastic effects. The underlying mechanisms remain to be
investigated; however, they involve the suppression of autophagy
[174], cyclooxygenase 2, and its product, prostaglandin E2 [175], as
well as the downregulation of LCOR [176] and IFN signaling mole-
cules [173,177]. Therefore, the two-edged functions of IFNs must be
considered in IFN-based cancer therapy.
3.8.3. CD200
CD200 provides a negative signal to CD200R-expressing mac-
rophages and DCs to induce immune tolerance [178]. The CD200/
CD200R axis may be involved in immune evasion of CSCs by sup-
pressing T-cell activation and Th1 cytokine production and
inducing regulatory DCs and Tregs [179]. For example, CD200 was
coexpressed with CSC markers in various types of cancers
[180e182]. The CD200 expression in leukemia predicted poor
prognosis in multiple myeloma and AML [179,183]. In B cell28lymphoma, the inhibition of CD200 by a neutralizing antibody or
siRNA increased the CTL response and the expression of inflam-
matory cytokines (IFNg and TNFa), resulting in lymphoma cell
death [184]. In HNSCC, CD200 overexpression induced the
expression of BMI1 and sonic hedgehog, both of which are involved
in the maintenance of CSCs [182]. Moreover, CD200 promoted
chemo- and radioresistance of squamous cell carcinoma in vivo
[182]. Therefore, CD200 may also be involved in the induction of
CSCs.
3.8.4. Other immunosuppressive molecules
Galectin-3, a b-galactoside-binding protein of the lectin family,
impairs tumor immunity through several mechanisms that remain
to be defined [185]. Lung CSCs were shown to express galectin-3,
which was significantly associated with CD133 and b-catenin in
lung cancer tissues [186]. Consistently, the overexpression of
galectin-3 induced CSC properties by activating b-catenin, which
promoted the transcription of stemness-related genes [186].
Galectin-3 also increased CSC properties of prostate cancer and
endowed CSCs with immune evasion and metastatic properties
[187].
Inhibitory leukocyte immunoglobulin-like receptors (LILRs) on
immune cells receive a negative signal from MHC-I molecules and
other unidentified ligands [188]. LILRB2 and LILRB3 were shown to
be expressed in AML and lung cancer and promoted their tumori-
genesis and stemness [189,190]. Fat mass- and obesity-associated
protein (FTO) is an RNA N6-methyladenosine demethylase that
expanded the CSC population of various cancers through LILRB4
upregulation [191]. Conversely, knockdown of FTO or treatment
with the FTO-specific demethylase inhibitors, CS1 and CS2, down-
regulated LILRB4 expression in leukemia cells, resulting in the
activation of the tumor immune response and the subsequent
suppression of tumor growth [191].
As summarized in Table 1, it is anticipated that CSCs employ
other molecules to create an immunosuppressive tumor microen-
vironment. Investigation of these mechanisms will assist in the
development of novel immunotherapies.
3.9. Immune modulation by CSC-intrinsic functions
Compared with non-CSCs, CSCs retain a more intact DNA repair
function that reduces immunogenicity [192]. As such, CSCs employ
their intrinsic functions to evade tumor immunity. Antiapoptosis
proteins, such as BCL2, BCLxL, and PI3K, may protect CSCs from T-
cell- and NK-cell-induced apoptosis [193,194]. Apoptosis inhibitor-
5, which was upregulated in CD44high CSCs, induced CSC properties
and suppressed the antigen-specific T-cell response in a fibroblast
growth factor 2-dependent manner [195,196]. STAT3 in CSCs may
also be involved in the expression of galectin-3 [42], suppression of
phagocytosis, and secretion of IL-10 from TAMs [197]. Likewise,
several CSC-regulating molecules, including NANOG [198,199],
SOX2 [200], DCLK1 [201,202], and CD73 [203,204], were shown to
be involved in immune evasion by CSCs.
4. Conclusions
Tumor immunity has opened new avenues for cancer therapy;
however, further improvements in efficacy are needed. The
mechanisms through which cancer cells evade the immune
response must be precisely clarified. In this article, we summarized
studies that clarified how CSCs suppress tumor immunity and
create an immunosuppressive milieu, which are expected to pro-
vide important clues for the development of novel tumor immu-
notherapies. Moreover, in agreement with the fact that cancer cells
must evade tumor immunity to form tumors, our literature survey
H. Tsuchiya and G. Shiota Regenerative Therapy 17 (2021) 20e33suggests that the immune evasion property, rather than the tumor-
initiating property, is a more fundamental feature of CSCs. In the
present article, the underlying mechanisms of immunosuppressive
properties of CSCs were summarized as: 1) the impairment of an-
tigen processing and presenting machineries; 2) the down-
regulation of tumor-associated antigens; 3) the downregulation of
NK-cell-activating ligands and upregulation of NK-cell inhibitory
ligands; 4) the inhibition of cytolytic granules released from CTL
and NK cells; 5) the secretion of immune suppressive humoral
factors, such as TGFb, IL-6, and CCL20; 6) the upregulation of
immunosuppressive molecules including immune checkpoint
molecules; and, 7) others. In order to suppress tumor immunity,
CSCs employ these mechanisms in combination. Therefore, CSCs
are expected to be a more effective target to restore tumor im-
munity than targeting each of the mechanisms individually. How-
ever, because of space limitations, we have reluctantly omitted
immune modulatory functions of noncancerous cells in the tumor
microenvironment, which also endow CSCs with the immune
evasion property and vice versa. Moreover, we would also like to
emphasize that additional factors, including hypoxia, cancer-
specific metabolites, and EMT, remain to be discussed but must
be considered for the development of immunotherapies. We expect
that an integrated understanding of these factors will lead to sig-
nificant improvements of current cancer immunotherapies.Declaration of competing interest
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